Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data
Fierce Pharma
Fri, 04/2/21 - 10:55 am
Tags:
Regeneron, FDA, Eylea, diabetic retinopathy, NIH
Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?
Motley Fool
Wed, 03/31/21 - 10:37 am
Tags:
Regeneron, vaccines, antibodies, COVID-19
Regeneron used Cuomo connections to get R&D chief Yancopoulos early COVID testing: NYT
Fierce Pharma
Fri, 03/26/21 - 10:49 am
Tags:
Regeneron, George Yancopoulos, Andrew Cuomo, COVID-19
Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases
Reuters
Tue, 03/23/21 - 10:42 am
Tags:
Regeneron, Roche, clincial trials, COVID-19
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Mon, 03/15/21 - 10:48 am
Tags:
Sanofi, Regeneron, Libtayo, cervical cancer, clinical trials
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Mon, 02/22/21 - 11:51 pm
Tags:
Regeneron, Libtayo, non-small cell lung cancer, Merck, Keytruda
Novartis’s canakinumab cancer test approaches
EP Vantage
Fri, 02/12/21 - 11:06 am
Tags:
Novartis, Regeneron, canakinumab, cancer, non-small cell lung cancer
Amgen loses appeal in patent suit against Sanofi/Regeneron’s Praluent. It’s a bummer for Bristol Myers Squibb and Merck, too
Endpoints
Fri, 02/12/21 - 10:48 am
Tags:
Amgen, patents, Sanofi, Regeneron, Praluent, Repatha, Merck
Regeneron's Evkeeza, carrying big price tag, wins FDA approval in ultra-rare cholesterol disease
Fierce Pharma
Thu, 02/11/21 - 10:36 pm
Tags:
Regeneron, Evkeeza, Homozygous Familial Hypercholesterolemia, FDA
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Yahoo/Benzinga
Wed, 02/10/21 - 10:32 am
Tags:
Sanofi, Regeneron, Libtayo, FDA, advanced basal cell carcinoma, skin cancer
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Endpoints
Mon, 02/8/21 - 10:25 am
Tags:
Dupixent, Regeneron, Sanofi, eczema
Mark Your Calendar For February PDUFA Dates
Yahoo/Benzinga
Sun, 01/31/21 - 10:18 pm
Tags:
FDA, Adamas Pharmaceuticals, Gocovri, Mallinckrodt, StrataGraft, Regeneron, evinacumab, Sanofi, Sarepta, TG Therapeutics
Regeneron COVID-19 drug cocktail combats South Africa variant, Lilly's does not - study
Reuters
Wed, 01/27/21 - 08:06 pm
Tags:
Regeneron, Eli Lilly, antibodies, COVID-19
Go or no go? Oncology decisions ahead for the FDA
EP Vantage
Wed, 01/27/21 - 11:55 am
Tags:
FDA, cancer, oncology, Bristol-Myers Squibb, TG Therapeutics, Mallinckrodt, Sanofi, Regeneron, Sarepta Therapeutics, GSK, Oncopeptide
Regeneron says monoclonal antibodies prevent Covid-19 in study
Stat
Tue, 01/26/21 - 11:34 am
Tags:
Regeneron, antibodies, COVID-19
Roche eyes FDA filing after bispecific matches Eylea again
Fierce Biotech
Mon, 01/25/21 - 10:44 am
Tags:
Roche, bispecifics, Regeneron, Eylea, clinical trials, faricimab, wet age-related macular degeneration
US to pay up to $2.6B for more doses of Regeneron's COVID-19 antibody drug
BioPharma Dive
Wed, 01/13/21 - 11:34 pm
Tags:
Regeneron, COVID-19, antibodies, government contracts
JPM: Regeneron has spoken with the FDA about odronextamab hold, hopes to get patients back soon
Fierce Biotech
Mon, 01/11/21 - 10:29 am
Tags:
Regeneron, FDA, odronextamab, clinical hold, B-cell non-Hodgkin lymphoma
Clinical developments over the holidays
EP Vantage
Mon, 01/4/21 - 10:17 am
Tags:
Aprea Therapeutics, Arcturus Therapeutics, Axsome Therapeutics, Inovio, Regeneron, clinical trials, oncology, vaccines, COVID-19
Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results
Marketwatch
Wed, 12/30/20 - 10:42 am
Tags:
Regeneron, COVID-19, antibodies

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.